Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain

Nat Rev Clin Oncol. 2024 Sep;21(9):643-644. doi: 10.1038/s41571-024-00907-w.

Authors

Maria Vittoria Dieci^{1

2}, Valentina Guarneri^{3

4}

Affiliations

¹ Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
² Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
³ Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. valentina.guarneri@unipd.it.
⁴ Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy. valentina.guarneri@unipd.it.

PMID: 38778084
DOI: 10.1038/s41571-024-00907-w

No abstract available

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Breast Neoplasms* / therapy
Erb-b2 Receptor Tyrosine Kinases / antagonists & inhibitors
Female
Humans
Precision Medicine*

Substances

Erb-b2 Receptor Tyrosine Kinases
ERBB2 protein, human